Dr. Eric K. Singhi discusses the significance of the FDA approval of subcutaneous Opdivo for patients with solid tumors.

Artificial Intelligence (AI) can be a great tool in diagnosing and management of atopic dermatitis -- a chronic skin condition -- leading to more accurate, early, and standardised identification ...

Experts shared diagnosis and management strategies for chronic pruritus at the Dermatology Days of Paris 2024 conference.

The most reported adverse reactions included fatigue, musculoskeletal pain, pruritus, rash and cough. The release states that the recommended dosage of subcutaneous nivolumab and hyaluronidase ...

The most common adverse reactions reported with Opdivo Qvantig were fatigue, musculoskeletal pain, pruritus, rash, and cough. Opdivo Qvantig is supplied in a single-dose vial containing nivolumab ...

The FDA has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), a new subcutaneous injection formulation of Opdivo.

The FDA has approved subcutaneous nivolumab and hyaluronidase-nvhy (Opdivo Qvantig) to treat a range of solid tumor malignancies.

Fatty liver disease, often associated with excessive alcohol consumption and poor diet, has been widely recognized for its ...

Use tabs only as continuation therapy to inj. Do not exceed 5 days' combined (inj + tabs) therapy or recommended dose (may use as-needed opioids for breakthrough pain if appropriate). After inj ...

In severe cases, it is associated with sleep disturbances due to pruritic rashes that appear on the skin during flare-ups, along with depression, anxiety, and loss of productivity. Effective ...